DBV Systems Announces Alter in U.S. Reporting Status and Closing Approval of World …
Montrouge, France, January 7, 2021
DBV Systems Announces Modify in U.S. Reporting Standing and Final Acceptance of World Restructuring Procedure
DBV Systems S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Sector: DBVT), a clinical-stage biopharmaceutical company, these days announced that it has established that it now qualifies as a U.S. domestic issuer fairly than a international personal issuer in the United States.
As of January 1, 2021, DBV Systems is subject matter to U.S. Securities and Exchange Fee (SEC) and other procedures and restrictions applicable to U.S. domestic issuers, in addition to applicable French and EU polices. DBV will be required to file with the SEC periodic reviews (together with existing experiences on Type 8-K and quarterly reviews on Sort 10-Q) and registration statements on U.S. domestic issuer kinds. Pursuant to SEC rules, the Organization will put together its consolidated monetary statements in accordance with typically accepted accounting concepts in the United States (US GAAP). Furthermore, the Corporation will continue to prepare consolidated economic statements in accordance with Worldwide Monetary Reporting Benchmarks (IFRS) as adopted by the European Union, for release in France and the European Union. Commencing January 1, 2021, the Company’s consolidated fiscal information and facts filed with the SEC and with the Autorité des marchés financiers (AMF) (including in the Company’s Common Registration Doc) will be reported in US dollars.
Today, the Organization also declared that the system implementing the Employment Safeguard Plan in France has been approved. DBV initiated this world wide restructuring plan in June 2020 to offer operational latitude to progress the clinical advancement and regulatory review of investigational Viaskin™ Peanut in the United States and European Union. The complete implementation of the restructuring strategy will end result in a reduction of a lot more than 200 positions, resulting in a remaining global group of 90 people focused to the pursuit of innovation and scientific advancement of novel therapies. DBV expects all head-rely reductions to be finished by the close of the very first quarter of 2021. DBV will keep its core knowledge in scientific enhancement, patch engineering and production, U.S. and EU market insights, and EPIT biology.
“ This acceptance represents a considerable milestone for DBV,” claimed Daniel Tasse, Main Executive Officer. “ We feel our restructuring endeavours will generate a leaner business, help us to reach better financial flexibility, and let us to most effective place ourselves as we navigate the late levels of scientific progress. I would like to thank all of our DBV colleagues, past and present, who have contributed to the development of epicutaneous immunotherapy and to celebrate the proficient staff that will propel us forward. This is a crew of people who embody our company values of collaboration, curiosity, courage, and reliability.”
As a outcome of the ongoing worldwide restructuring, DBV has been equipped to simplify company processes throughout the Company’s world functions. DBV Technologies expects ongoing deceleration in its typical month-to-month funds melt away by the 2nd 50 % of 2021. DBV Technologies expects whole implementation of the corporation-broad value reduction measures to be accomplished by the 2nd half of 2021, at which position DBV forecasts it will have decreased its ordinary monthly money melt away by 40-50% as compared to the very first half of 2020. Based on latest assumptions regarding the progress of its regulatory dossier and in mild of the final acceptance of the strategy, DBV expects these price tag-reduction efforts to considerably prolong the Company’s dollars runway to the second half of 2022.
About DBV Technologies
DBV Technologies is establishing Viaskin™, an investigational proprietary technologies platform with broad possible apps in immunotherapy. Viaskin is dependent on epicutaneous immunotherapy, or EPIT™, DBV’s process of providing biologically lively compounds to the immune program through intact pores and skin. With this new class of non-invasive merchandise candidates, the Business is dedicated to safely transforming the treatment of foodstuff allergic sufferers. DBV’s foodstuff allergic reactions packages include things like ongoing clinical trials of Viaskin Peanut. DBV Systems has world wide headquarters in Montrouge, France and workplaces in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s common shares are traded on section B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each individual symbolizing a single-fifty percent of a single everyday share) are traded on the Nasdaq World-wide Decide on Market (Ticker: DBVT).
Forward Searching Statements
This push launch may include forward-hunting statements and estimates, which includes statements pertaining to the implementation of the Company’s worldwide restructuring system, the likely benefits of the proposed restructuring of the Company’s business enterprise and the Company’s capability to realize individuals benefits, potential cost discounts, the Company’s forecast of its money runway and reduced monthly income burn off, the preparing of new and added monetary statements, and predicted future filings with U.S., E.U., and French securities regulators. These ahead-seeking statements and estimates are not claims or assures and contain sizeable dangers and uncertainties. At this phase, the solutions of the Firm have not been licensed for sale in any place. Among the the components that could induce real benefits to differ materially from all those described or projected herein involve uncertainties linked frequently with analysis and growth, clinical trials and associated regulatory opinions and approvals, like the effects of the COVID-19 pandemic, the Company’s means to efficiently execute on its restructuring ideas, the Company’s capacity to get ready economic statements in accordance with US GAAP, and risks connected to the regulatory and compliance stress linked with reporting as a U.S. domestic issuer. In addition, the timing of any motion by any regulatory entity are not able to be assured, especially in light-weight of the COVID-19 pandemic. A even further list and description of threats and uncertainties that could lead to true results to differ materially from individuals established forth in the forward-looking statements in this press launch can be identified in the Company’s regulatory filings with the French AMF, the Company’s SEC filings and stories, together with in the Company’s Annual Report on Kind 20-F for the 12 months ended December 31, 2019, and long run filings and reviews by the Organization. Current and prospective buyers are cautioned not to location undue reliance on these forward-looking statements and estimates, which converse only as of the date hereof. Other than as demanded by relevant legislation, DBV Technologies undertakes no obligation to update or revise the information and facts contained in this press launch.
Trader Relations Make contact with
Anne Pollak
+ 1 (857) 529-2363
[email protected]
Media Contact
Angela Marcucci
+1 (646) 842-2393
[email protected]
Attachment
